Can endothelin A receptor antibodies alter signaling and vascular tone without proving pathogenicity?

In a 77-year-old man, an elevated endothelin-A receptor (ETAR) antibody result should be interpreted as an immunologic finding rather than proof of an active vascular disease mechanism. The overall claim is supported: some ETAR antibodies can modify receptor signaling and vascular tone, but serum positivity alone does not establish functional pathogenicity.

Functional and vascular evidence

• Experimental ETAR antibodies have shown both agonist and blocking behavior. Agonistic antibodies—reported to recognize the second extracellular loop—can mimic endothelin-1, producing ERK/MAPK activation and calcium-linked signaling. Blocking/neutralizing antibodies can inhibit endothelin-1-induced intracellular calcium elevation, ERK1/2 phosphorylation, and AKT-related responses.
• This biology is relevant to vascular tone: patient IgG preparations containing AT1R and ETAR antibodies induced resistance-artery vasoconstriction; this was attenuated by receptor blockade and MEK–ERK inhibition. However, coexisting AT1R and other antibodies limit attribution of that response to ETAR alone.

Mechanistic context

• ETAR predominantly couples through Gq/11–PLCβ, generating IP3-mediated intracellular calcium release, PKC activation, ERK1/2 signaling, and vascular smooth-muscle contraction.
• In systemic-sclerosis-derived experimental systems, ETAR-antibody-positive purified IgG activated endothelial cells and increased fibroblast collagen-I expression; ETAR-selective or dual endothelin-receptor blockade reduced these effects. These findings support plausible vasculopathic and profibrotic mechanisms in selected antibody preparations.

Interpretation of a serum result

• Commercial ELISAs measure antibody binding, not receptor activation, blockade, endothelial injury, vasoconstriction, or clinical causality. Thresholds are not harmonized across platforms, and antibody concentration does not reliably predict functional activity.
• Establishing activity requires controlled receptor/cell-based testing, ideally using purified IgG plus ETAR blockade and/or receptor-knockdown controls.

Bottom line

• ETAR antibodies can plausibly alter signaling and vascular tone, in either direction, but an elevated serum value is a biomarker—not evidence by itself that the antibodies are functionally pathogenic or clinically responsible for disease.